ABIOMED INC Form 8-K August 15, 2005

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 8-K

## CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report: August 10, 2005 (Date of earliest event reported)

### ABIOMED, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or Other Jurisdiction of Incorporation)

04-2743260 (IRS Employer Identification Number)

001-09585

(Commission File Number)

22 Cherry Hill Drive

22 Cherry Hill Drive 4

## Edgar Filing: ABIOMED INC - Form 8-K Danvers, MA 01923

(Address of Principal Executive Offices, including Zip Code)

(978) 777-5410

(Registrant s Telephone Number, including Area Code)

Not Applicable

Not Applicable 5

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Not Applicable 6

#### Item 1.01 Entry into a Material Definitive Agreement.

On August 10, 2005, we held our annual meeting of stockholders. At the meeting, our stockholders approved an amendment to our 2000 Stock Incentive Plan. The amendment increased the number of shares of our common stock issuable under the plan from 2,900,000 to 4,900,000. A copy of the plan, as amended, is attached as appendix A to our definitive proxy statement filed with the Securities and Exchange Commission on July 15, 2005.

2

Not Applicable 7

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ABIOMED, Inc.

By: /s/ Charles B. Haaser

Charles B. Haaser Controller

Principal Accounting Officer Principal Financial Officer

Date: August 12, 2005

3

Controller 9